Expression of mTOR Signaling Pathway Molecules in Triple-Negative Breast Cancer | Zendy

Kei Ito | Zendy; Hideaki Ogata | Zendy; Naoko Honma | Zendy; Kazutoshi Shibuya | Zendy; Tetuo Mikami | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Expression of mTOR Signaling Pathway Molecules in Triple-Negative Breast Cancer

Author(s) -

Kei Ito,

Hideaki Ogata,

Naoko Honma,

Kazutoshi Shibuya,

Tetuo Mikami

Publication year - 2019

Publication title -

pathobiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.941

H-Index - 53

eISSN - 1423-0291

pISSN - 1015-2008

DOI - 10.1159/000503311

Subject(s) - triple negative breast cancer , pi3k/akt/mtor pathway , cancer research , estrogen receptor , glut3 , rptor , cell growth , biology , signal transduction , chemistry , breast cancer , cancer , glut1 , medicine , microbiology and biotechnology , endocrinology , glucose transporter , biochemistry , insulin

Triple-negative breast cancer (TNBC), which lacks expression of estrogen receptor (ER), progesterone receptor (PgR), and epidermal growth factor receptor 2 (HER2), currently has no effective hormonal or molecular target therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research